

FIG. 1





FIG. 2



AEs = adverse events; ALA = alpha-linolenic acid; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LA = linoleic acid; LDL-C = low-density lipoprotein cholesterol; LLT = lipid-lowering therapy; MTD = maximum tolerated dose

1. Stabilise current LLT (including LA, when applicable), establish diet <20% energy from fat or <30 g fat, whichever is the lesser amount, dietary supplementation from Week -2 (daily 200 IU [5 to 8 years of age] 400 IU [≥9 years of age] vitamin E and EPA supplement [approx. 200 mg linoleic acid, 210 mg ALA, 110 mg EPA, and 80 mg DHA])
2. During the 24-week efficacy phase, patients will be required to remain on the stable LLT regimen (including LA, when applicable) established during the 6-week run-in period
3. Based on safety, tolerability and efficacy parameters
4. Adjustments to background LLT (including LA, when applicable) will be allowed at the discretion of the investigator
5. Dose adjustment rules apply
6. Eligible patients who complete the study per protocol may choose to enter the long-term extension of this study, pending approval by appropriate ethics committees and regulatory authorities; for patients who opt not to participate in the long-term extension of this study or who are ineligible, there will be a 4-week Follow-up period during which study medication is discontinued and patients will remain on concomitant LLT (including LA, when applicable).